louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04758832: The Effect of Poorly Designed School Furniture on Children's Head and Scapulae Postures
Official title: The Effect of Poorly Designed School Furniture on Children's Head and Scapulae Postures: A Cross Sectional Design
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ergonomics
Lead sponsor: Delta University for Science and Technology
Sponsor class: OTHER
First posted: 2021-02-17
Enrollment: 200
Sex: ALL
Minimum age (years): 7
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Two hundred and fifty-seven normal children were evaluated for eligibility; thirty-five children were excluded because they failed to fulfill the inclusion criteria and sixteen parents refused to enrolled in this study.

Brief summary: investigate the compatibility of school furniture design


Eligibility criteria: Inclusion Criteria:

* had normal body mass index (ranged from 18.5 to 24.9 kg/ m2),
* The school furniture workstations used by all subjects were all of wooden flat desks and benches.

Exclusion Criteria:

* suffering from respiratory or heart problems

Primary outcomes:
measure: weight
timeFrame: up to 24 weeks
measure: height
timeFrame: up to 24 weeks
measure: Body mass index (BMI)
timeFrame: up to 24 weeks
measure: anthropometric measurement for child
timeFrame: up to 24 weeks
measure: anthropometric measurement for school furniture
timeFrame: up to 24 weeks
Secondary outcomes:
measure: Correlation between educational furniture dimensions and the user body dimensions
timeFrame: through study completion, an average of 1 year.
measure: Head postures (angles)
timeFrame: through study completion, an average of 1 year.
measure: scapular postures (displacement and elevation).
timeFrame: through study completion, an average of 1 year.
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: AAA
Study officials:
References:
Clinical trial NCT00528632: Gallbladder Cholesterolosis, Body Mass Index and Serum Cholesterol and Triglycerides
Official title: Association of Gallbladder Cholesterolosis to Body Mass Index and Levels of Serum Cholesterol and Triglycerides.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gallstones
Gallbladder Cholesterolosis
Keywords: Gallstones
Gallbladder
Cholesterolosis
Serum cholesterol
triglycerides
Body Mass Index
Lead sponsor: Cirujanos la Serena
Sponsor class: OTHER
First posted: 2007-09-12
Enrollment: 406
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients operated on elective basis for symtomatic gallbladder lithiasis

Brief summary: Cholesterolosis is a common finding in biopsy specimens of gallbladders surgically removed for cholelithiasis.

To the best of the investigators knowledge no study has analyzed the relationships of Body Mass Index, serum Cholesterol and Triglycerides and gallbladder cholesterolosis.

The purpose of this study is to analyze and find relations between gallbladder cholesterolosis, Body Mass Index, serum cholesterol and triglycerides.

Detailed description: A prospective database including the following variables was filled out:

* Age
* Gender
* Diagnosis
* Weight
* Height
* Body Mass Index
* Histopathological results (Biopsy)
* Serum cholesterol
* Serum triglycerides

All elective patients older than 15 years of age submitted to cholecystectomy for symptomatic gallstones were included. Plasma cholesterol and triglycerides levels were measured 5 to 7 days before surgery. Only patients with chronic cholecystitis and with cholesterolosis according to the histology of the surgical specimen were included, we did not include any patient with acute cholecystitis or gallbladder cancer.

Eligibility criteria: Inclusion Criteria:

* Patients submitted to elective cholecystectomy
* Histopathological report of gallbladder cholesterolosis
* Histopathological report of chronic cholecystitis
* Patients older than 15 years of age

Exclusion Criteria:

* Patients younger than 15 years of age
* Pathological report missing from the hospital records

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: La Serena
country: Chile
facility: Hospital De La Serena
state: Iv Region
Study officials:
affiliation: Hospital de La Serena
name: Marcelo A Beltran, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital De La Serena - HISTOMED
name: Carlos Barria, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05160532: Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis
Official title: Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Knee Osteoarthritis
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-12-16
Enrollment: 48
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to learn more about treating Symptomatic Knee Osteoarthritis (OA) with an ultrasound-guided hypertonic dextrose injection. Researchers would like to determine best practice for injection frequency and effectiveness of the dextrose injection for symptomatic knee OA.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of knee OA by clinical criteria (American College of Rheumatology).
* Identification of knee osteoarthritis by a radiologist on an existing knee radiograph obtained within 3 years of enrollment.
* Moderate to severe knee pain for at least 3 months, defined as a score of ≥ 4 (on a 0-10 point numeric rating scale) in response to the question "What is the average level of your left/right knee pain in the past 3 months?".

Exclusion Criteria:

* Pregnancy.
* Diabetes.
* Anticoagulation therapy.
* History of total knee replacement.
* Prior knee prolotherapy or other regenerative product.
* Any knee injection within 3 months.
* Inflammatory (RA, gout, pseudogout etc.) or postinfectious knee arthritis.
* Daily use of opioid medication.
* Allergy or intolerance to study medication, corn allergy.
* Body mass index (BMI) greater than 40 kg/m\^2.
* Comorbidity severe enough to prevent participation in the study protocol.

Primary outcomes:
measure: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
timeFrame: Baseline, 4 weeks, 8 weeks, 16 weeks, 26 weeks, and 52 weeks
Secondary outcomes:
measure: Change in pain
timeFrame: Baseline, 4 weeks, 8 weeks, 16 weeks, 26 weeks, and 52 weeks
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
Study officials:
affiliation: Mayo Clinic
name: David Patchett, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04588532: Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch
Official title: Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Itch
Lead sponsor: Aalborg University
Sponsor class: OTHER
First posted: 2020-10-19
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: With this experiment, the experimenter wish to asses if substance BAM8-22 (Bovine Adrenal Medulla) induce non-histaminergic itch.

Detailed description: With this experiment, the experimenter wish to establish if the substance BAM8-22 (Bovine Adrenal Medulla) induce a non-histaminergic itch by using the antihistamine Doxepin.

The experimenter will also compare itch and the response to antihistamine of BAM8-22, histamine and cowhage.

Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* 18-60 years
* Speak and understand English

Exclusion Criteria:

* Pregnancy or lactation
* Drug addiction defined as any use of cannabis, opioids or other drugs
* Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.)
* Moles, wounds, scars or tattoos in the area to be treated or tested
* Lack of ability to cooperate •
* Current use of medications that may affect the trial such as antihistamines and pain killers.
* Skin diseases
* Consumption of alcohol or painkillers 24 hours before the study days and between these - Acute or chronic pain •
* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)

Primary outcomes:
measure: superficial blood perfusion
timeFrame: change from baseline, up to 10 minutes after the first session
measure: Warm Detection Threshold, and Heat Pain threshold
timeFrame: change from baseline, up to 10 minutes after the first session
measure: Cold Detection Threshold and Cold Pain threshold
timeFrame: change from baseline, up to 10 minutes after the first session
measure: Pain supra-threshold heat Stimuli
timeFrame: change from baseline, up to 10 minutes after the first session
measure: hyperknesis (abnormal pruriceptive state)
timeFrame: change from baseline, up to 10 minutes after the first session
measure: mechanical pain threshold and sensitivity
timeFrame: change from baseline, up to 10 minutes after the first session
measure: itch rating
timeFrame: change from baseline, up to 10 minutes after the first session
Secondary outcomes:
measure: pain rating
timeFrame: change from baseline, up to 10 minutes after the first session
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg University
Study officials:
References:
Clinical trial NCT03830632: Effects Of Plyometric Training Program On Speed And Agility In Young Cricketers
Official title: Effects Of Plyometric Training Program On Speed And Agility In Young Cricketers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physical Fitness
Lead sponsor: Zohra Institute of Health Sciences
Sponsor class: OTHER
First posted: 2019-02-05
Enrollment: 40
Sex: MALE
Minimum age (years): 14
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: OTHER

Brief summary: This study was to determine the effects of plyometric training program on speed and agility in young cricketer. There were two groups, one received plyometric training program and other received training training to improve speed and agility in young cricketers

Detailed description: Plyometric training has been an effective method for the improvement of agility, sprinting, and jumping ability and it has also been reported to Improve running economy, joint stability, increased joint awareness and overall proprioception and decrease the severity of knee injuries. In the Plyometric exercise involves starting, stopping, and change of movement directions which contribute to agility development.The athletes use plyometric training techniques in many sports to improve explosive power and body strength. The plyometrics is a rapid stretch of muscle (eccentric) contraction straight away shortening (concentric) contraction in similar muscle tissue

Eligibility criteria: Inclusion Criteria:

°The male professional cricketers with age between 14-24 years old from Islamabad were included.

Exclusion Criteria:

° Cricketers not engaged in game from last 1 month.

Primary outcomes:
measure: Speed Test (10 meter sprint test)
timeFrame: 8 Weeks
measure: Agility T-Test
timeFrame: 8 Weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01803932: Evaluation of a Male-focused Intervention to Prevent Intimate Partner Violence in a Conflict-affected Setting
Official title: Evaluation of a Male-focused Primary Prevention Intervention to Prevent Intimate Partner Violence in a Conflict-affected Setting: A Cluster Randomized Controlled Trial in Cote d'Ivoire
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Domestic Violence
Keywords: intimate partner violence
gender
primary prevention intervention
conflict
Cote d'Ivoire
Ivory Coast
Lead sponsor: London School of Hygiene and Tropical Medicine
Sponsor class: OTHER
Collaborators: name: International Rescue Committee
First posted: 2013-03-04
Enrollment: 601
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Cluster randomized controlled trial to evaluate a male-focused primary prevention programme which used a men's only group discussion format to prevent intimate partner violence against women \& girls through fostering knowledge and behaviour changes by: (1) increasing men's knowledge on the impact of violence against women; (2) promoting gender equitable beliefs/behaviours within relationships; and (3) developing anger management techniques.


Eligibility criteria: Inclusion Criteria:

* 15+ years old
* males: participant in group intervention or selected as control
* females: female intimate partner of males in intervention or selected as control
* capable of completing face-to-face interview independently and without causing undue psychological distress

Exclusion Criteria:

* lack of informed consent

Primary outcomes:
measure: Past 12 months victimisation/perpetration of physical or sexual intimate partner violence
timeFrame: 1 year after intervention completion
Secondary outcomes:
Other outcomes:
Locations:
city: Abidjan
country: Côte D'Ivoire
facility: International Rescue Committee
Study officials:
affiliation: London School of Hygiene and Tropical Medicine
name: Mazeda Hossain
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hossain M, Zimmerman C, Kiss L, Abramsky T, Kone D, Bakayoko-Topolska M, Annan J, Lehmann H, Watts C. Working with men to prevent intimate partner violence in a conflict-affected setting: a pilot cluster randomized controlled trial in rural Cote d'Ivoire. BMC Public Health. 2014 Apr 10;14:339. doi: 10.1186/1471-2458-14-339.
Clinical trial NCT00228332: A Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares
Official title: A Double-Blind, Placebo-Controlled Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Verrucae Vulgares
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2005-09-28
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Double-blind, placebo-controlled trial investigating the effect of a treatment with zinkgluconaat for verrucae vulgares

Detailed description: A Double-blind, placebo-controlled trial investigating the effect of a treatment with zinkgluconaat for verrucae vulgares

Eligibility criteria: Inclusion Criteria:

* Patients with verrucae vulgares

Exclusion Criteria:

Primary outcomes:
measure: Disappearence of the verrucae vulgares after 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Annelies Stockman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03847532: MUTYH-associated Polyposis
Official title: Diagnosis and Treatment of Russian Patients With MutYH-associated Polyposis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: MutYH-associated Polyposis
Keywords: MutYH-associated polyposis
familial adenomatous polyposis
biallelic mutation
monoallelic mutation
colproctectomy
Lead sponsor: State Scientific Centre of Coloproctology, Russian Federation
Sponsor class: OTHER_GOV
First posted: 2019-02-20
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 71
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is single-center, prospective, non-randomized study

Detailed description: The study will include patients with more than 3 polyps, without mutations in the APC gene. Using molecular genetic research methods (polymerase chain reaction, SSCP, sequencing by Sanger method) mutations in the MutYH gene will be studied. For all patients with mutations in the MutYH gene, an optimal diagnostic algorithm will be developed. The significance of monoallelic mutations in the MutYH gene will be determined. Clinical monitoring will be defined. Optimal amount of surgical intervention will be suggested.

Eligibility criteria: Inclusion Criteria:

1. patients with multiple colon polyps (n polyps = 4+)
2. patient consent to participate in the study

Exclusion Criteria:

1. presence of mutations in the APC gene
2. patient's refusal to participate in the study

Primary outcomes:
measure: Patients with germIine mutations in MutYH
timeFrame: from 0 to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: State Scientific Centre of Coloproctology
Study officials:
References:
Clinical trial NCT03305432: Preoperative PPI in Sleeve Gastrectomy
Official title: Routine Preoperative PPI in Sleeve Gastrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Morbid Obesity
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2017-10-10
Enrollment: 120
Sex: ALL
Minimum age (years): 16
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: he purpose of this study is to study the effect of preoperative PPI in the early outcome of sleeve gastrectomy

Detailed description: In this study 200 morbidly obese patients will be included and will be undergone sleeve gastrectomy. the patients will be randomly assigned into 2 groups, group 1 will be receive PPI preoperative for 10 day and group 2 will not

Eligibility criteria: Inclusion Criteria:

* Morbidly obese patient with BMI more than 40 with or without co-morbidity
* Morbidly obese patient with BMI more than 35 with co-morbidity

Exclusion Criteria:

* Unfit patients for laparoscopic sleeve gastrectomy
* patients refuse to share in the study
* patients that already on PPI due to any indications
* revisional surgery for obesity
* previous upper abdominal surgery

Primary outcomes:
measure: early postoperative bleeding and leak
timeFrame: 2 weeks
Secondary outcomes:
measure: operative time
timeFrame: 5 hours
measure: microscopic picture of the removed stomach
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Faculty of medicine
Study officials:
References:
Clinical trial NCT00782132: Access to Infertility Services: Clinic Perspective
Official title: Access to Infertility Services in Ontario for Couples in Which One or Both Partners is HIV-Positive
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility
Keywords: Infertility Services, HIV, pregnancy planning
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2008-10-31
Enrollment: 23
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Ontario clinics offering advanced reproductive/infertility services

Brief summary: Since the identification of the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS) in the 1980s, there have been significant advances made in the management and long-term prognosis for infected individuals. Currently, with the advent of highly active antiretroviral therapy (HAART), HIV-positive individuals may live a healthy and productive life for years to decades after diagnosis. As life expectancy has increased, this group of people has begun to engage in family planning. This has created a need for access to advanced reproductive technologies and fertility treatments. While attempting to achieve pregnancy, utilization of these services can help to minimize the risk of transmission in serodiscordant couples, and can allow treatment of subfertile couples. Access to these services may be limited in Ontario for a variety of reasons. The purpose of this study is to determine the access to infertility clinics and services in Ontario for couples in which one or both partners is infected with HIV.


Eligibility criteria: Inclusion Criteria:

* All Ontario clinics offering advanced reproductive/infertility services

Exclusion Criteria:

* none

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
Study officials:
affiliation: Women's College Research Institute
name: Mona Loutfy, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yudin MH, Shapiro HM, Loutfy MR. Access to infertility services in Canada for HIV-positive individuals and couples: a cross-sectional study. Reprod Health. 2010 May 12;7:7. doi: 10.1186/1742-4755-7-7.
Clinical trial NCT00442832: TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
Official title: A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Staphylococcal Skin Infection
Keywords: cSSSI
Staph
MRSA
Lead sponsor: Theravance Biopharma
Sponsor class: INDUSTRY
First posted: 2007-03-02
Enrollment: 203
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.

Detailed description: TD-1792 is compared to vancomycin for the treatment of cSSSI.

Eligibility criteria: Inclusion Criteria:

* major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections
* requires at least 7 days of intravenous antibiotic treatment

Exclusion Criteria:

* more than 24 hours of antibiotic therapy
* moderate or severe liver disease
* severely neutropenic
* baseline QTc \> 500 msec, congenital long QT syndrome, uncompensated heart failure, uncorrected abnormal K+ or Mg++ blood levels or severe left ventricular hypertrophy

Primary outcomes:
measure: Clinical response
timeFrame: 7 to 14 days after last antibiotic dose
Secondary outcomes:
Other outcomes:
Locations:
city: National City
country: United States
facility: Allan Churukian
state: California
Study officials:
affiliation: Theravance Biopharma
name: Medical Monitor
role: STUDY_DIRECTOR
References: